Cyclo(his-pro) TFA Cyclo(histidyl-proline TFA; Histidylproline diketopiperazine TFA)|cas:936749-56-3|西域试剂

Cyclo(his-pro) TFA Cyclo(histidyl-proline TFA; Histidylproline diketopiperazine TFA),99.06%

产品编号：Bellancom-101402A| CAS NO：936749-56-3| 分子式：C₁₃H₁₅F₃N₄O₄| 分子量：348.28

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-101402A		￥500.00	杭州北京（现货）
Bellancom-101402A		￥900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Cyclo(his-pro) TFA Cyclo(histidyl-proline TFA; Histidylproline diketopiperazine TFA)

产品介绍

Cyclo(his-pro) TFA (Cyclo(histidyl-proline) TFA) 是一种具有口服活性的，结构上与促甲状腺激素释放激素相关的环状二肽。Cyclo(his-pro) TFA 可以抑制 NF-κB 核积累。Cyclo(his-pro) TFA 可以穿越脑血屏障并影响多种炎症和应激反应。

生物活性

Cyclo(his-pro) TFA (Cyclo(histidyl-proline) TFA) is an orally active cyclic dipeptide structurally related to tyreotropin-releasing hormone. Cyclo(his-pro) TFA could inhibit NF-κB nuclear accumulation. Cyclo(his-pro) TFA can cross the brain-blood-barrier and affect diverse inflammatory and stress responses.

体外研究

Cyclo(his-pro) TFA (Cyclo(histidyl-proline) TFA; 50 μM; 1-48 hours) increases the nuclear level of Nrf2 and inhibits NF-κB nuclear translocation. Cyclo(His-Pro) alone has no effect on nuclear translocation of these transcription factors.
Cyclo(his-pro) TFA (50 μM; prior to PQ exposure for 48 hours) abolishes protein nitration that followed paraquat (PQ) exposure and lessenes its functional consequences, as shown by decrease in cell apoptosis, detected by caspase 3 activity and by cytochrome c release.
Cyclo(his-pro) TFA inhibits NF-κB nuclear accumulation induced by paraquat in rat pheochromocytoma PC12 cells via the Nrf2/heme oxygenase-1 pathway.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	PC12 cells
Concentration:	50 μM
Incubation Time:	1, 2, 4, 8, 24, 48 hours
Result:	Increased the nuclear level of Nrf2 and inhibited NF-κB nuclear translocation.

体内研究
(In Vivo)

Cyclo(his-pro) TFA (Cyclo(histidyl-proline) TFA; 1.8 mg/ear; topical application on the right ear; 30 min prior to TPA) reduces TPA-induced ear oedema confirming that it can exert anti-inflammatory effect.
Cyclo(his-pro) TFA exerts in vivo anti-inflammatory effects in the central nervous system by down-regulating hepatic and cerebral TNFα expression thereby counteracting LPS-induced gliosis. Moreover, by up-regulating Bip, Cyclo(his-pro) increases the ER stress sensitivity andtriggers the unfolded protein response to alleviate the ER stress.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sixty two/three month-old male C57BL/6 mice (25-30 g)
Dosage:	1.8 mg/ear
Administration:	Topical application on the right ear; 30 min prior to TPA
Result:	Reduced TPA-induced ear oedema.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sixty two/three month-old male C57BL/6 mice (25-30 g)
Dosage:	1.8 mg/ear
Administration:	Topical application on the right ear; 30 min prior to TPA
Result:	Reduced TPA-induced ear oedema.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sixty two/three month-old male C57BL/6 mice (25-30 g)
Dosage:	1.8 mg/ear
Administration:	Topical application on the right ear; 30 min prior to TPA
Result:	Reduced TPA-induced ear oedema.

性状

Solid

溶解性数据

In Vitro:

DMSO : 260 mg/mL (746.53 mM; Need ultrasonic)

H₂O : 125 mg/mL (358.91 mM; ultrasonic and adjust pH to 10 with NaOH)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8713 mL	14.3563 mL	28.7125 mL
5 mM	0.5743 mL	2.8713 mL	5.7425 mL
10 mM	0.2871 mL	1.4356 mL	2.8713 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 100 mg/mL (287.13 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.17 mg/mL (6.23 mM); Clear solution

此方案可获得 ≥ 2.17 mg/mL (6.23 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.17 mg/mL (6.23 mM); Clear solution

此方案可获得 ≥ 2.17 mg/mL (6.23 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.17 mg/mL (6.23 mM); Clear solution

此方案可获得 ≥ 2.17 mg/mL (6.23 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。